Galicaftor structure
|
Common Name | Galicaftor | ||
---|---|---|---|---|
CAS Number | 1918143-53-9 | Molecular Weight | 559.46 | |
Density | 1.6±0.1 g/cm3 | Boiling Point | 701.1±60.0 °C at 760 mmHg | |
Molecular Formula | C28H21F4NO7 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 377.8±32.9 °C |
Use of GalicaftorGalicaftor (ABBV-2222; GLPG-2222) is a potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Galicaftor can be used for cystic fibrosis research[1]. |
Name | ABBV-2222 (GLPG2222) |
---|---|
Synonym | More Synonyms |
Description | Galicaftor (ABBV-2222; GLPG-2222) is a potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Galicaftor can be used for cystic fibrosis research[1]. |
---|---|
Related Catalog | |
In Vitro | Galicaftor (ABBV-2222; GLPG-2222) exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR, with an EC50 <10 nM[2]. |
In Vivo | The rat pharmacokinetic tests are performed on Galicaftor (ABBV-2222; GLPG-2222; 1 mg/kg, i.v.; 1 mg/kg, p.o.) to illustrate its pharmacokinetic properties in rats. The T1/2 is 2.7 hours (i.v.). And for intragastric administration, the bioavailability (%F) is 74%[1]. |
References |
Density | 1.6±0.1 g/cm3 |
---|---|
Boiling Point | 701.1±60.0 °C at 760 mmHg |
Molecular Formula | C28H21F4NO7 |
Molecular Weight | 559.46 |
Flash Point | 377.8±32.9 °C |
Exact Mass | 559.125427 |
LogP | 6.05 |
Vapour Pressure | 0.0±2.3 mmHg at 25°C |
Index of Refraction | 1.640 |
Benzoic acid, 4-[(2R,4R)-4-[[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-7-(difluoromethoxy)-3,4-dihydro-2H-1-benzopyran-2-yl]- |
4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid |
galicaftor |